search reports
Categories
Categories

Global and United States Benign Prostatic Hyperplasia Medication In-Depth Research Report 2017-2022

Report Code : usmi0080
Published Date : 01 August, 2017 | No of Pages: 127

  • Report Description
  • Table of Contents
  • Related Reports
The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022.

This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Benign Prostatic Hyperplasia Medication industry.

Major Companies
MSD PHARMA (SINGAPORE) PTE.LTD.
Merck Sharp & Dohme Limited
GlaxoSmithKline (Ireland) Limited
Pfizer Pharma GmbH
Sanofi-Aventis France
ABBOTT LABORATORIES
Astellas Pharma Inc.
AMNEAL PHARMS
ANCHEN PHARMS
APOTEX INC
ASCENT PHARMS INC
AUROBINDO PHARMA
BARR
BIONPHARMA INC
BOEHRINGER INGELHEIM
BRECKENRIDGE PHARM
CIPLA LTD
AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
CIPLA LIMITED IN 400 013 Mumbai
CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
EXCELLA GMBH & CO. KG DE 90537 Feucht
Farmak A.S. CZ 779 00 Olomouc
HETERO LABS LIMITED IN 500 018 Hyderabad
Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

Key Regions
North America
United States
California
Texas
New York
Others
Canada
Latin America
Mexico
Brazil
Argentina
Others
Europe
Germany
United Kingdom
France
Italy
Spain
Russia
Netherland
Others
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Indonesia
Thailand
Philippines
Vietnam
Singapore
Malaysia
Others
Africa & Middle East
South Africa
Egypt
Turkey
Saudi Arabia
Iran
Others

Main types of products
Benign Prostatic Hyperplasia Medication Market, by 5α-reductase inhibitors
Finasteride
Dutasteride
Epristeride
Benign Prostatic Hyperplasia Medication Market, by α-receptor antagonist
Pheoxbenzamine
Doxazosin
Alfuzosin
Terazosin
Prarizonaosin
Tamsulosin
Naftopidil
Benign Prostatic Hyperplasia Medication Market, by Plant Preparations
Prostat
Cernilton
Compound blue palm fruit
Benign Prostatic Hyperplasia Medication Market, by Others
Flavoxate
glu-ala-glycine

Benign Prostatic Hyperplasia Medication Market, by Key Consumers
urinary surgery
Pharmacy
Hospital
Clinic

Table of Contents

Global and United States Benign Prostatic Hyperplasia Medication In-Depth Research Report 2017-2022
Chapter One Global Benign Prostatic Hyperplasia Medication Market Overview
1.1 Global Benign Prostatic Hyperplasia Medication Market Sales Volume Revenue and Price 2012-2017
1.2 Benign Prostatic Hyperplasia Medication, by 5α-reductase inhibitors 2012-2017
1.2.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors 2012-2017
1.2.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors 2012-2017
1.2.3 Global Benign Prostatic Hyperplasia Medication Price by 5α-reductase inhibitors 2012-2017
1.2.4 Finasteride
1.2.5 Dutasteride
1.2.6 Epristeride
1.3 Benign Prostatic Hyperplasia Medication, by α-receptor antagonist 2012-2017
1.3.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist 2012-2017
1.3.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist 2012-2017
1.3.3 Global Benign Prostatic Hyperplasia Medication Price by α-receptor antagonist 2012-2017
1.3.4 Pheoxbenzamine
1.3.5 Doxazosin
1.3.6 Alfuzosin
1.3.7 Terazosin
1.3.8 Prarizonaosin
1.3.9 Tamsulosin
1.3.10 Naftopidil
1.4 Benign Prostatic Hyperplasia Medication, by Plant Preparations 2012-2017
1.4.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations 2012-2017
1.4.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations 2012-2017
1.4.3 Global Benign Prostatic Hyperplasia Medication Price by Plant Preparations 2012-2017
1.4.4 Prostat
1.4.5 Cernilton
1.4.6 Compound blue palm fruit
1.5 Benign Prostatic Hyperplasia Medication, by Others 2012-2017
1.5.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others 2012-2017
1.5.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others 2012-2017
1.5.3 Global Benign Prostatic Hyperplasia Medication Price by Others 2012-2017
1.5.4 Flavoxate
1.5.5 glu-ala-glycine

Chapter Two United States Benign Prostatic Hyperplasia Medication Market Overview
2.1 United States Benign Prostatic Hyperplasia Medication Market Sales Volume Revenue and Price 2012-2017
2.2 Benign Prostatic Hyperplasia Medication, by 5α-reductase inhibitors 2012-2017
2.2.1 United States Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors 2012-2017
2.2.2 United States Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors 2012-2017
2.2.3 United States Benign Prostatic Hyperplasia Medication Price by 5α-reductase inhibitors 2012-2017
2.2.4 Finasteride
2.2.5 Dutasteride
2.2.6 Epristeride
2.3 Benign Prostatic Hyperplasia Medication, by α-receptor antagonist 2012-2017
2.3.1 United States Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist 2012-2017
2.3.2 United States Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist 2012-2017
2.3.3 United States Benign Prostatic Hyperplasia Medication Price by α-receptor antagonist 2012-2017
2.3.4 Pheoxbenzamine
2.3.5 Doxazosin
2.3.6 Alfuzosin
2.3.7 Terazosin
2.3.8 Prarizonaosin
2.3.9 Tamsulosin
2.3.10 Naftopidil
2.4 Benign Prostatic Hyperplasia Medication, by Plant Preparations 2012-2017
2.4.1 United States Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations 2012-2017
2.4.2 United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations 2012-2017
2.4.3 United States Benign Prostatic Hyperplasia Medication Price by Plant Preparations 2012-2017
2.4.4 Prostat
2.4.5 Cernilton
2.4.6 Compound blue palm fruit
2.5 Benign Prostatic Hyperplasia Medication, by Others 2012-2017
2.5.1 United States Benign Prostatic Hyperplasia Medication Sales Market Share by Others 2012-2017
2.5.2 United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Others 2012-2017
2.5.3 United States Benign Prostatic Hyperplasia Medication Price by Others 2012-2017
2.5.4 Flavoxate
2.5.5 glu-ala-glycine

Chapter Three Benign Prostatic Hyperplasia Medication by Regions 2012-2017
3.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions 2012-2017
3.2 Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions 2012-2017
3.3 Global Benign Prostatic Hyperplasia Medication Price by Regions 2012-2017
3.4 North America
3.4.1 United States
3.4.1.1 California
3.4.1.2 Texas
3.4.1.3 New York
3.4.1.4 Others in United States
3.4.2 Canada
3.5 Latin America
3.5.1 Mexico
3.5.2 Brazil
3.5.3 Argentina
3.5.4 Others in Latin America
3.6 Europe
3.6.1 Germany
3.6.2 United Kingdom
3.6.3 France
3.6.4 Italy
3.6.5 Spain
3.6.6 Russia
3.6.7 Netherland
3.6.8 Others in Europe
3.7 Asia & Pacific
3.7.1 China
3.7.2 Japan
3.7.3 India
3.7.4 Korea
3.7.5 Australia
3.7.6 Southeast Asia
3.7.6.1 Indonesia
3.7.6.2 Thailand
3.7.6.3 Philippines
3.7.6.4 Vietnam
3.7.6.5 Singapore
3.7.6.6 Malaysia
3.7.6.7 Others in Southeast Asia
3.8 Africa & Middle East
3.8.1 South Africa
3.8.2 Egypt
3.8.3 Turkey
3.8.4 Saudi Arabia
3.8.5 Iran
3.8.6 Others in Africa & Middle East

Chapter Four Global Benign Prostatic Hyperplasia Medication by Companies 2012-2017
4.1 Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Companies 2012-2017
4.2 Global Benign Prostatic Hyperplasia Medication Revenue Share by Companies 2012-2017
4.3 Global Top Companies Benign Prostatic Hyperplasia Medication Key Product Model and Market Performance
4.4 Global Top Companies Benign Prostatic Hyperplasia Medication Key Target Consumers and Market Performance

Chapter Five United States Benign Prostatic Hyperplasia Medication by Companies 2012-2017
5.1 United States Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Companies 2012-2017
5.2 United States Benign Prostatic Hyperplasia Medication Revenue Share by Companies 2012-2017
5.3 United States Top Companies Benign Prostatic Hyperplasia Medication Key Product Model and Market Performance
5.4 United States Top Companies Benign Prostatic Hyperplasia Medication Key Target Consumers and Market Performance

Chapter Six Global Benign Prostatic Hyperplasia Medication by Consumer 2012-2017
6.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer 2012-2017
6.2 urinary surgery
6.3 Pharmacy
6.4 Hospital
6.5 Clinic
6.6 Consuming Habit and Preference

Chapter Seven Global Benign Prostatic Hyperplasia Medication by Consumer 2012-2017
7.1 Global Benign Prostatic Hyperplasia Medication Sales Market Share by Consumer 2012-2017
7.2 urinary surgery
7.3 Pharmacy
7.4 Hospital
7.5 Clinic
7.6 Consuming Habit and Preference

Chapter Eight Top Companies Profile
8.1 MSD PHARMA (SINGAPORE) PTE.LTD.
8.1.1 MSD PHARMA (SINGAPORE) PTE.LTD. Company Details and Competitors
8.1.2 MSD PHARMA (SINGAPORE) PTE.LTD. Key Benign Prostatic Hyperplasia Medication Models and Performance
8.1.3 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.1.4 MSD PHARMA (SINGAPORE) PTE.LTD. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.2 Merck Sharp & Dohme Limited
8.2.1 Merck Sharp & Dohme Limited Company Details and Competitors
8.2.2 Merck Sharp & Dohme Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
8.2.3 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.2.4 Merck Sharp & Dohme Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.3 GlaxoSmithKline (Ireland) Limited
8.3.1 GlaxoSmithKline (Ireland) Limited Company Details and Competitors
8.3.2 GlaxoSmithKline (Ireland) Limited Key Benign Prostatic Hyperplasia Medication Models and Performance
8.3.3 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.3.4 GlaxoSmithKline (Ireland) Limited Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.4 Pfizer Pharma GmbH
8.4.1 Pfizer Pharma GmbH Company Details and Competitors
8.4.2 Pfizer Pharma GmbH Key Benign Prostatic Hyperplasia Medication Models and Performance
8.4.3 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.4.4 Pfizer Pharma GmbH Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.5 Sanofi-Aventis France
8.5.1 Sanofi-Aventis France Company Details and Competitors
8.5.2 Sanofi-Aventis France Key Benign Prostatic Hyperplasia Medication Models and Performance
8.5.3 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.5.4 Sanofi-Aventis France Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.6 ABBOTT LABORATORIES
8.6.1 ABBOTT LABORATORIES Company Details and Competitors
8.6.2 ABBOTT LABORATORIES Key Benign Prostatic Hyperplasia Medication Models and Performance
8.6.3 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.6.4 ABBOTT LABORATORIES Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.7 Astellas Pharma Inc.
8.7.1 Astellas Pharma Inc. Company Details and Competitors
8.7.2 Astellas Pharma Inc. Key Benign Prostatic Hyperplasia Medication Models and Performance
8.7.3 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.7.4 Astellas Pharma Inc. Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.8 AMNEAL PHARMS
8.8.1 AMNEAL PHARMS Company Details and Competitors
8.8.2 AMNEAL PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
8.8.3 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.8.4 AMNEAL PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.9 ANCHEN PHARMS
8.9.1 ANCHEN PHARMS Company Details and Competitors
8.9.2 ANCHEN PHARMS Key Benign Prostatic Hyperplasia Medication Models and Performance
8.9.3 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.9.4 ANCHEN PHARMS Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.10 APOTEX INC
8.10.1 APOTEX INC Company Details and Competitors
8.10.2 APOTEX INC Key Benign Prostatic Hyperplasia Medication Models and Performance
8.10.3 APOTEX INC Benign Prostatic Hyperplasia Medication Business SWOT Analysis and Forecast
8.10.4 APOTEX INC Benign Prostatic Hyperplasia Medication Sales Volume Revenue Price Cost and Gross Margin
8.11 ASCENT PHARMS INC
8.12 AUROBINDO PHARMA
8.13 BARR
8.14 BIONPHARMA INC
8.15 BOEHRINGER INGELHEIM
8.16 BRECKENRIDGE PHARM
8.17 CIPLA LTD
8.18 AUROBINDO PHARMA LIMITED IN 500 038 Hyderabad
8.19 Bioindustria L.I.M. S.p.A. IT 15067 Novi Ligure
8.20 CADILA HEALTHCARE LIMITED IN 391 440 Dabhasa Village
8.21 CIPLA LIMITED IN 400 013 Mumbai
8.22 CRYSTAL PHARMA S.A.U. ES 47151 Boecillo
8.23 DR. REDDY'S LABORATORIES LIMITED IN 500 034 Hyderabad
8.24 EXCELLA GMBH & CO. KG DE 90537 Feucht
8.25 Farmak A.S. CZ 779 00 Olomouc
8.26 HETERO LABS LIMITED IN 500 018 Hyderabad
8.27 Hubei Gedian Humanwell Pharmaceutical Co., Ltd. CN 436 070 E-Zhou
8.28 MSN LABORATORIES PRIVATE LIMITED IN 502 329 Rudraram Village

Chapter Nine Industry Chain and Supply Chain
9.1 Benign Prostatic Hyperplasia Medication Industry Chain Structure
9.1.1 R&D
9.1.2 Raw Materials (Components)
9.1.3 Manufacturing Plants
9.1.4 Regional Trading (Import Export and Local Sales)
9.1.5 Online Sales Channel
9.1.6 Offline Channel
9.1.7 End Users
9.2 Benign Prostatic Hyperplasia Medication Manufacturing
9.2.1 Key Components
9.2.2 Assembly Manufacturing
9.3 Consumer Preference
9.4 Behavioral Habits
9.5 Marketing Environment

Chapter Ten Global Benign Prostatic Hyperplasia Medication Market Size (Sales and Revenue) Forecast (2017-2022)
10.1 Global Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
10.2 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
10.3 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
10.4 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by 5α-reductase inhibitors (2017-2022)
10.5 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by α-receptor antagonist (2017-2022)
10.6 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Plant Preparations (2017-2022)
10.7 Global Benign Prostatic Hyperplasia Medication Sales () Forecast by Others (2017-2022)

Chapter Eleven United States Benign Prostatic Hyperplasia Medication Market Size (Sales and Revenue) Forecast (2017-2022)
11.1 United States Benign Prostatic Hyperplasia Medication Sales (), Revenue (Million USD) Forecast (2017-2022)
11.2 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by Regions (2017-2022)
11.3 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by Application (2017-2022)
11.4 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by 5α-reductase inhibitors (2017-2022)
11.5 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by α-receptor antagonist (2017-2022)
11.6 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by Plant Preparations (2017-2022)
11.7 United States Benign Prostatic Hyperplasia Medication Sales () Forecast by Others (2017-2022)

Chapter Twelve Development Trend and Research Conclusion
12.1 Development Trend
12.2 Research Conclusion

Chapter Thirteen Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer


List of Tables and Figures

Table Global Benign Prostatic Hyperplasia Medication Sales Volume (), Revenue (Million USD) and Price ()(2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by 5α-reductase inhibitors (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by 5α-reductase inhibitors (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors in 2016
Table Global Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
Table Top Companies of Finasteride Benign Prostatic Hyperplasia Medication Products List
Figure Global Finasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Dutasteride Benign Prostatic Hyperplasia Medication Products List
Figure Global Dutasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Epristeride Benign Prostatic Hyperplasia Medication Products List
Figure Global Epristeride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by α-receptor antagonist (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by α-receptor antagonist (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist in 2016
Table Global Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
Table Top Companies of Pheoxbenzamine Benign Prostatic Hyperplasia Medication Products List
Figure Global Pheoxbenzamine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Doxazosin Benign Prostatic Hyperplasia Medication Products List
Figure Global Doxazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Alfuzosin Benign Prostatic Hyperplasia Medication Products List
Figure Global Alfuzosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Terazosin Benign Prostatic Hyperplasia Medication Products List
Figure Global Terazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Prarizonaosin Benign Prostatic Hyperplasia Medication Products List
Figure Global Prarizonaosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by Plant Preparations (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Plant Preparations (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations in 2016
Table Global Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
Table Top Companies of Prostat Benign Prostatic Hyperplasia Medication Products List
Figure Global Prostat Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Cernilton Benign Prostatic Hyperplasia Medication Products List
Figure Global Cernilton Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Compound blue palm fruit Benign Prostatic Hyperplasia Medication Products List
Figure Global Compound blue palm fruit Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by Others (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Others in 2016
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Others (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Others in 2016
Table Global Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
Table Top Companies of Flavoxate Benign Prostatic Hyperplasia Medication Products List
Figure Global Flavoxate Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of glu-ala-glycine Benign Prostatic Hyperplasia Medication Products List
Figure Global glu-ala-glycine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Growth Rate (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Volume () and Growth Rate (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales () by 5α-reductase inhibitors (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Market Share by 5α-reductase inhibitors in 2016
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by 5α-reductase inhibitors (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by 5α-reductase inhibitors in 2016
Table United States Benign Prostatic Hyperplasia Medication Price () by 5α-reductase inhibitors (2012-2017)
Table Top Companies of Finasteride Benign Prostatic Hyperplasia Medication Products List
Figure United States Finasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Dutasteride Benign Prostatic Hyperplasia Medication Products List
Figure United States Dutasteride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Epristeride Benign Prostatic Hyperplasia Medication Products List
Figure United States Epristeride Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales () by α-receptor antagonist (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Market Share by α-receptor antagonist in 2016
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by α-receptor antagonist (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by α-receptor antagonist in 2016
Table United States Benign Prostatic Hyperplasia Medication Price () by α-receptor antagonist (2012-2017)
Table Top Companies of Pheoxbenzamine Benign Prostatic Hyperplasia Medication Products List
Figure United States Pheoxbenzamine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Doxazosin Benign Prostatic Hyperplasia Medication Products List
Figure United States Doxazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Alfuzosin Benign Prostatic Hyperplasia Medication Products List
Figure United States Alfuzosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Terazosin Benign Prostatic Hyperplasia Medication Products List
Figure United States Terazosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Prarizonaosin Benign Prostatic Hyperplasia Medication Products List
Figure United States Prarizonaosin Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales () by Plant Preparations (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Market Share by Plant Preparations in 2016
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Plant Preparations (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Plant Preparations in 2016
Table United States Benign Prostatic Hyperplasia Medication Price () by Plant Preparations (2012-2017)
Table Top Companies of Prostat Benign Prostatic Hyperplasia Medication Products List
Figure United States Prostat Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Cernilton Benign Prostatic Hyperplasia Medication Products List
Figure United States Cernilton Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of Compound blue palm fruit Benign Prostatic Hyperplasia Medication Products List
Figure United States Compound blue palm fruit Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales () by Others (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales Market Share by Others (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Market Share by Others in 2016
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Others (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Others (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Others in 2016
Table United States Benign Prostatic Hyperplasia Medication Price () by Others (2012-2017)
Table Top Companies of Flavoxate Benign Prostatic Hyperplasia Medication Products List
Figure United States Flavoxate Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Top Companies of glu-ala-glycine Benign Prostatic Hyperplasia Medication Products List
Figure United States glu-ala-glycine Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Share by Regions (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2016
Figure Global Benign Prostatic Hyperplasia Medication Sales Market Share by Regions in 2017
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) and Market Share by Regions (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2016
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Regions in 2017
Table Global Benign Prostatic Hyperplasia Medication Price () by Regions (2012-2017)
Table North America Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table North America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure North America Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Latin America Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Latin America Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure Latin America Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Europe Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Europe Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure Europe Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Asia & Pacific Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Asia & Pacific Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure Asia & Pacific Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Africa & Middle East Benign Prostatic Hyperplasia Medication Sales () by Regions (2012-2017)
Table Africa & Middle East Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Regions (2012-2017)
Figure Africa & Middle East Benign Prostatic Hyperplasia Medication Sales () and Growth Rate (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Volume () by Major Companies (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Major Companies (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Major Companies 2016
Figure Global Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Major Companies 2017
Table Global Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Major Companies (2012-2017)
Table Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Major Companies (2012-2017)
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Major Companies 2016
Figure Global Benign Prostatic Hyperplasia Medication Revenue Market Share by Major Companies 2017
Table Global Top Companies Key Product Model and Market Performance
Table Global Top Companies Key Target Consumers and Market Performance
Table United States Benign Prostatic Hyperplasia Medication Sales Volume () by Top Companies (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Top Companies (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Top Companies 2016
Figure United States Benign Prostatic Hyperplasia Medication Sales Volume Market Share by Top Companies 2017
Table United States Benign Prostatic Hyperplasia Medication Revenue (Million USD) by Top Companies (2012-2017)
Table United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Top Companies (2012-2017)
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Top Companies 2016
Figure United States Benign Prostatic Hyperplasia Medication Revenue Market Share by Top Companies 2017
Table United States Top Companies Key Product Model and Ma
Market Intel Report Global and United States Bacillus Subtilis Depth Research Report 2017-2022
By: US Market Insight | Published Date : 26 July, 2017 | No of Pages : 108
Market Intel Report Global and United States Antipsychotic drugs Depth Research Report 2017-2022
By: US Market Insight | Published Date : 20 July, 2017 | No of Pages : 116
Market Intel Report Global and United States Respiratory system durgs In-Depth Research Report 2017-2022
By: US Market Insight | Published Date : 01 August, 2017 | No of Pages : 123
Market Intel Report Global and United States Cardiovascular system drugs Depth Research Report 2017-2022
By: US Market Insight | Published Date : 02 August, 2017 | No of Pages : 158
Market Intel Report Global and United States Blood system drugs In-Depth Research Report 2017-2022
By: US Market Insight | Published Date : 01 August, 2017 | No of Pages : 125
Please select License
Single User Price:$ 3190
Enterprise Price:$ 6380